This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
| Age and bodyweight | Dosage | Frequency | Infusion time (minutes) |
|---|---|---|---|
| Neonates from birth to <2 months† | 6 mg/kg | Every 8 hours | 60 |
| 2 months to <2 years | 8 mg/kg | Every 8 hours | 5-60†‡ |
| 2 years to <12 years | 12 mg/kg up to 400 mg | Every 8 hours | 5-60†‡ |
| 12 years to <18 years and bodyweight <33 kg | 12 mg/kg up to 400 mg | Every 8 hours | 5-60†‡ |
| 12 years to <18 years and bodyweight ≥33 kg | 600 mg | Every 12 hours | 5-60†‡ |
A high-dose regimen† is also available for paediatric patients aged ≥2 months with cSSTI confirmed or suspected to be caused by S. aureus with an MIC = 2 mg/L or 4 mg/L to Zinforo (refer to dosing tables within the SmPC for more detailed information).
For high dose regimen recommendations for patients with renal impairment, refer to dosing tables within the SmPC.
*Calculated using the Schwartz formula for paediatric patients (in mL/min/1.73 m2). 1
¶Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function.1
†Infusion times of <60 minutes, neonatal and high-dose recommendations are based on PK/PD analyses only.1
‡ Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis).1 Infusion times of <60 minutes are based on PK/PD analyses only.1
** Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
Abbreviations
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CrCL, creatinine clearance; MIC, minimum inhibitory concentration.
Prescribing Information
Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion
References
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021